Heart Failure in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032

List of Contents

About GlobalData

List of Contents

List of Tables

List of Figures

1 Heart Failure: Executive Summary – Updated October 2024, Based on Events up to October 24, 2024

1.1 The HF market will exhibit strong growth between 2022 and 2032

1.2 Label expansions of CV drugs will fuel market growth

1.3 Unmet needs remain in the HF market despite the availability of well-established therapies

1.4 Injectable agents will dominate the HF market

1.5 What do physicians think?

2 Introduction – Updated October 2024, Based on Events up to October 24, 2024

2.1 Catalyst

2.2 Related reports

3 Disease Overview

3.1 Etiology and pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.1.3 Biomarkers/targets of interest

3.2 Classification or staging systems

3.3 Prognosis

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 Forecast methodology

4.4.1 Sources

4.4.2 Forecast assumptions and methods

4.4.3 Forecast assumptions and methods: diagnosed incident cases of HF – 7MM

4.4.4 Forecast assumptions and methods: diagnosed incident cases of HF by ejection fraction

4.4.5 Forecast assumptions and methods: hospitalizations for acute HF

4.4.6 Forecast assumptions and methods: acute HF hospitalizations based on presentation

4.4.7 Forecast assumptions and methods: hospital length of stay days for acute HF hospitalizations

4.4.8 Forecast assumptions and methods: re-admissions within 30 days post-discharge after acute HF hospitalization

4.4.9 Forecast assumptions and methods: diagnosed prevalent cases of HF – 7MM

4.4.10 Forecast assumptions and methods: diagnosed prevalent cases of HF by ejection fraction

4.4.11 Forecast assumptions and methods: diagnosed prevalent cases of HF by New York Heart Association classes

4.4.12 Forecast assumptions and methods: diagnosed prevalent cases of HF with preserved ejection fraction (left ventricular ejection fraction ≥50%) by New York Heart Association class

4.4.13 Forecast assumptions and methods: diagnosed prevalent cases of HF with mid-range ejection fraction (left ventricular ejection fraction 40–49%) by New York Heart Association class

4.4.14 Forecast assumptions and methods: diagnosed prevalent cases of HF with reduced ejection fraction (left ventricular ejection fraction <40%) by New York Heart Association class

4.4.15 Forecast assumptions and methods: diagnosed prevalent cases of HF by American College of Cardiology Foundation/American Heart Association stages

4.5 Epidemiological forecast for HF (2022–32)

4.5.1 Diagnosed incident cases of HF

4.5.2 Age-specific diagnosed incident cases of HF

4.5.3 Sex-specific diagnosed incident cases of HF

4.5.4 Diagnosed incident cases of HF by ejection fraction

4.5.5 Hospitalizations for acute HF

4.5.6 Acute HF hospitalizations based on presentation

4.5.7 Hospital length of stay for acute HF

4.5.8 Re-admissions within 30 days post-discharge after acute HF

4.5.9 Diagnosed prevalent cases of HF

4.5.10 Age-specific diagnosed prevalent cases of HF

4.5.11 Sex-specific diagnosed prevalent cases of HF

4.5.12 Diagnosed prevalent cases of HF by ejection fraction

4.5.13 Diagnosed prevalent cases of HF by New York Heart Association class

4.5.14 Diagnosed prevalent cases of HF with preserved ejection fraction (left ventricle ejection fraction ≥50%) by New York Heart Association class

4.5.15 Diagnosed prevalent cases of HF with mid-range ejection fraction (left ventricle ejection fraction 40–49%) by New York Heart Association class

4.5.16 Diagnosed prevalent cases of HF with reduced ejection fraction (left ventricle ejection fraction <40%) by New York Heart Association class

4.5.17 Diagnosed prevalent cases of HF by American College of Cardiology Foundation/American Heart Association stages

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 COVID-19 impact

4.6.3 Limitations of the analysis

4.6.4 Strengths of the analysis

5 Disease Management – Updated October 2024, Based on Events up to October 24, 2024

5.1 Diagnosis and treatment overview

5.2 KOL insights on disease management

6 Current Treatment Options – Updated October 2024, Based on Events up to October 24, 2024

6.1 Overview

7 Unmet Needs and Opportunity Assessment – Updated October 2024, Based on Events up to October 24, 2024

7.1 Overview

7.2 Lack of therapies for HF with preserved ejection fraction patients

7.3 Lack of therapies for acute HF

7.4 Compliance and optimal management of HF treatments

7.5 Preventative therapies for patients at risk of developing HF

8 R&D Strategies – Updated October 2024, Based on Events up to October 24, 2024

8.1 Overview

8.1.1 Label expansion for therapies approved for other indications

8.1.2 Mergers and acquisitions to expand the product pipeline

8.2 Clinical trials design

8.2.1 Clinical endpoints for HF

8.2.2 Inclusion and exclusion criteria

9 Pipeline Assessment – Updated October 2024, Based on Events up to October 24, 2024

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis – Updated October 2024, Based on Events up to October 24, 2024

10.1 Overview

10.2 Competitive assessment

11 Current and Future Players – Updated October 2024, Based on Events up to October 24, 2024

11.1 Overview

11.2 Deal-making trends

12 Market Outlook – Updated October 2024, Based on Events up to October 24, 2024

12.1 Global markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting methodology

13.4 Primary research – KOLs interviewed for this report

13.4.1 KOLs

13.5 Primary research – prescriber survey

13.6 About the authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Vice President of Disease Intelligence and Epidemiology

13.6.5 Global Head of Pharma Research, Analysis, and Competitive Intelligence

Contact Us

Table 1: Heart failure: key metrics in the 7MM

Table 2: Types of chronic HF

Table 3: Causes of HF

Table 4: Compensatory mechanisms in HF patients

Table 5: Symptoms of HF

Table 6: Types of chronic HF

Table 7: Comparison of two HF classification systems

Table 8: Risk factors and comorbidities for HF

Table 9: Treatment guidelines for HF

Table 10: Top 10 deals by value, 2019–24

Table 11: HF market – global drivers and barriers, 2022–32

Table 12: Key events impacting sales for HF in the US, 2022–32

Table 13: HF market – drivers and barriers in the US, 2022–32

Table 14: Key events impacting sales for HF in the 5EU, 2022–32

Table 15: HF market – drivers and barriers in the 5EU, 2022–32

Table 16: Key events impacting sales for HF in Japan, 2022–32

Table 17: HF market – drivers and barriers in Japan, 2022–32

Table 18: High-prescribing physicians (non-KOLs) surveyed, by country

Figure 1: Global sales forecast by country for HF in 2022 and 2032

Figure 2: Analysis of the company portfolio gap in HF during the forecast period

Figure 3: Competitive assessment of the injectable late-stage pipeline agents that GlobalData expects to be licensed for the treatment of HF during the forecast period

Figure 4: Competitive assessment of the oral late-stage pipeline agents that GlobalData expects to be licensed for the treatment of HF during the forecast period

Figure 5: Changes in cardiac structure in HF

Figure 6: 7MM, diagnosed incidence of HF (cases per 100,000 population), men and women, all ages, 2022

Figure 7: 7MM, diagnosed prevalence of HF (%), men and women, all ages, 2022

Figure 8: 7MM, sources used and not used to forecast the diagnosed incident cases of HF

Figure 9: 7MM, sources used to forecast the diagnosed incident cases of HF by EF

Figure 10: 7MM, sources used to forecast the hospitalization for acute HF

Figure 11: 7MM, sources used to forecast the hospitalizations for acute HF by presentation

Figure 12: 7MM, sources used to forecast the hospital LoS for acute HF

Figure 13: 7MM, sources used to forecast the re-admissions within 30 days post-discharge after acute HF hospitalization

Figure 14: 7MM, sources used to forecast the diagnosed prevalent cases of HF

Figure 15: 7MM, sources used to forecast the diagnosed prevalent cases of HF by EF

Figure 16: 7MM, sources used to forecast the diagnosed prevalent cases of HF by NYHA class

Figure 17: 7MM, sources used to forecast the diagnosed prevalent cases of HF-PEF, HF-mrEF, and HF-REF by NYHA class

Figure 18: 7MM, sources used to forecast the diagnosed prevalent cases of HF by EF

Figure 19: 7MM, diagnosed incident cases of HF, N, both sexes, all ages, 2022

Figure 20: 7MM, diagnosed incident cases of HF by age, N, both sexes, 2022

Figure 21: 7MM, diagnosed incident cases of HF by sex, N, all ages, 2022

Figure 22: 7MM, diagnosed incident cases of HF by EF, N, both sexes, all ages, 2022

Figure 23: 7MM, hospitalizations for acute HF, N, both sexes, all ages, 2022

Figure 24: 7MM, acute HF hospitalizations based on presentation, N, both sexes, all ages, 2022

Figure 25: 7MM, hospital LoS for acute HF, days, both sexes, all ages, 2022

Figure 26: 7MM, re-admissions within 30 days post-discharge after acute HF hospitalization, N, both sexes, all ages, 2022

Figure 27: 7MM, diagnosed prevalent cases of HF, N, both sexes, all ages, 2022

Figure 28: 7MM, diagnosed prevalent cases of HF by age, N, both sexes, 2022

Figure 29: 7MM, diagnosed prevalent cases of HF by sex, N, all ages, 2022

Figure 30: 7MM, diagnosed prevalent cases of HF by sex, N, all ages, 2022

Figure 31: 7MM, diagnosed prevalent cases of HF by NYHA classes, N, both sexes, all ages, 2022

Figure 32: 7MM, diagnosed prevalent cases of HF-PEF (LVEF ≥50%) by NYHA class, N, both sexes, all ages, 2022

Figure 33: 7MM, diagnosed prevalent cases of HF-mrEF (LVEF = 40–49%) by NYHA class, N, both sexes, all ages, 2022

Figure 34: 7MM, diagnosed prevalent cases of HF-REF (LVEF <40%) by NYHA class, N, both sexes, all ages, 2022

Figure 35: 7MM, diagnosed prevalent cases of HF by ACCF/AHA stages, N, both sexes, all ages, 2022

Figure 36: Diagnosis algorithm for chronic HF

Figure 37: Unmet needs and opportunities in chronic and acute HF

Figure 38: Overview of the development pipeline in HF

Figure 39: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for HF in the 7MM during the forecast period

Figure 40: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of HF during the forecast period

Figure 41: Competitive assessment of the oral pipeline drugs benchmarked against the standard of care (SOC)

Figure 42: Competitive assessment of the injectable pipeline drugs benchmarked against the standard of care (SOC)

Figure 43: Analysis of the company portfolio gap in HF during the forecast period

Figure 44: Global (7MM) sales forecast by country for HF in 2022 and 2032

Figure 45: Sales forecast by class for HF in the US in 2022 and 2032

Figure 46: Sales forecast by class for HF in the 5EU in 2022 and 2032

Figure 47: Sales forecast by class for HF in Japan in 2022 and 2032